Brief: Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold On Azenosertib Studies
16/09/2024 12:35
Sept 16 (Reuters) - Zentalis Pharmaceuticals Inc
ZNTL.O :
* ZENTALIS PHARMACEUTICALS ANNOUNCES FDA HAS LIFTED PARTIAL
CLINICAL HOLD ON AZENOSERTIB STUDIES
* ZENTALIS PHARMACEUTICALS INC - ON TRACK TO MEET 2024 DATA
GUIDANCE
* ZENTALIS PHARMACEUTICALS INC - FDA CLEARS RESUMPTION OF
ALL
AZENOSERTIB CLINICAL STUDIES
* ZENTALIS PHARMACEUTICALS INC - TO RESUME AZENOSERTIB STUDY
ACTIVITIES IMMEDIATELY
Source text for Eikon: ID:nGNX747brk
Further company coverage: ZNTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer